Coronavirus company news summary – Abbott’s rapid antigen test receives CE Mark for asymptomatic screening and self-administration – Innova Medical Group starts Covid rapid test kit production in California

27 January 2021 (Last Updated January 27th, 2021 09:26)

Abbott has received a CE Mark for its Panbio Covid-19 Ag rapid test device, which allows self-administration collection through a nasal swab. The test enables mass testing among individuals who do not show symptoms of the disease.

Fluidigm Corporation has announced that Helix Specialty Diagnostics and Genomic LTC DX have collaborated to provide Covid-19 testing with the help of the Advanta™ Dx SARS-CoV-2 RT-PCR Assay on Fluidigm’s Biomark HD system. Helix will enable sample collection, while Genomic will process and analyse the saliva samples with the Advanta Dx Assay on Biomark HD.

Innova Medical Group has officially initiated the production of its INNOVA SARS-CoV-2 Antigen Rapid Qualitative Test kit in Southern California. The company intends to expand its capacity from five million test kits per day by February to 50 million rapid test kits per day at its expanded facilities across Orange County, California.

OraSure Technologies has announced that Chronomics Limited, a biotechnology company, has selected its OMNIgene ORAL (OME-505) saliva collection device for its SARS CoV-2 PCR test. Chronomics will provide the test for UK’s Test to Release for International Travel programme.